OPTIMANCT05394116
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 24 versions: 22 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Results posted: Nov 17, 2026
- Primary endpoint(s) modified
- Eligibility criteria shortened, about 4 words
- Secondary endpoints: 16 to 23
- Minor Primary completion date changed from estimate of Jul 31, 2025 to Jul 17, 2025v21
- Notable Eligibility criteria revised
- Primary completion date: Aug 4, 2025 to Jul 31, 2025
- Study completion date: Sep 25, 2026 to Feb 27, 2029
- Notable Primary endpoints revised (2)
- Primary completion date: Jul 31, 2025 to Aug 4, 2025
- Study completion date: Oct 2, 2026 to Sep 25, 2026
- Secondary endpoints revised (16)
Minor Trial status: Recruiting to Active, Not Recruitingv18 Show 4 more changesShow less
- Enrollment target: estimated 66 to confirmed 63
- Study sites: 23 to 22
- Primary completion date: Apr 10, 2025 to Jul 31, 2025
- Study completion date: Jun 12, 2026 to Oct 2, 2026
Show 16 earlier versionsHide 16 earlier versions
- Minor Secondary endpoints revised (16)
- Site details revised at 1 of 23 sites
- Minor Study sites: 22 to 23
- Eligibility criteria revised
- Minor Study sites: 20 to 22v15
- Minor Study sites: 17 to 20v14
Notable Primary endpoints revised (2)v13 Show 4 more changesShow less
- Eligibility criteria expanded, about 1 word
- Study completion date: Apr 10, 2026 to Jun 12, 2026
- Secondary endpoints revised (16)
- Study title expanded, about 2 words
- Minor Study sites: 16 to 17v12
- Minor Study sites: 9 to 16v11
- Minor Study sites: 8 to 9v10
- Minor Study sites: 7 to 8v9
- Minor Study sites: 6 to 7v8
- Minor Study sites: 4 to 6v7
- Minor Study sites: 2 to 4
- Primary completion date: Mar 5, 2025 to Apr 10, 2025
- Study completion date: Mar 5, 2026 to Apr 10, 2026
- Minor Study sites: 1 to 2v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
Notable Start date: Sep 29, 2022 to Nov 21, 2022v3 Show 4 more changesShow less
- Eligibility criteria shortened, about 2 words
- Study sites: 0 to 1
- Primary completion date: Mar 8, 2025 to Mar 5, 2025
- Study completion date: Mar 8, 2025 to Mar 5, 2026
- Notable Start date: Jul 14, 2022 to Sep 29, 2022
- Study completion date: Mar 8, 2026 to Mar 8, 2025
- Secondary endpoints: 15 to 16
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (20)
Show 15 moreShow less
Arms and interventions
Garetosmab is administered by intravenous (IV) administration every 4 weeks (Q4W)
Garetosmab is administered by IV administration Q4W
Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV Q4W.
Drugs: Garetosmab, Placebo
Sites
22 sites in 18 countries
Japan 3, France 2, United States 2, Australia 1, Brazil 1, Chile 1, China 1, Colombia 1, Finland 1, Hong Kong 1, Italy 1, Malaysia 1, Netherlands 1, Poland 1, South Africa 1, South Korea 1, Spain 1, United Kingdom 1